Doxycycline in Creutzfeldt-Jakob disease: A phase 2, randomised, double-blind, placebo-controlled trial

The Lancet Neurology

Volumn 13, Issue 2, 2014, Pages 150-158

  Haïk, Stéphane ^a,b   Marcon, Gabriella ^c,d   Mallet, Alain ^b   Tettamanti, Mauro ^e   Welaratne, Arlette ^b   Giaccone, Giorgio ^c   Azimi, Shohreh ^f   Pietrini, Vladimiro ^g   Fabreguettes, Jean Roch ^f   Imperiale, Daniele ^h   Cesaro, Pierre ^f   Buffa, Carlo ^h   Aucan, Christophe ^f   Lucca, Ugo ^e   Peckeu, Laurène ^a,b   Suardi, Silvia ^c   Tranchant, Christine ⁱ   Zerr, Inga ^j   Houillier, Caroline ^a,b   Redaelli, Veronica ^c   Vespignani, Hervé ^k   Campanella, Angela ^c   Sellal, François ^l   Krasnianski, Anna ^j   Seilhean, Danielle ^a,b   Heinemann, Uta ^j   Sedel, Frédéric ^b   Canovi, Mara ^e   Gobbi, Marco ^e   Di Fede, Giuseppe ^c   Laplanche, Jean Louis ^f   Pocchiari, Maurizio ^m   Salmona, Mario ^e   Forloni, Gianluigi ^e   Brandel, Jean Philippe ^a,b   Tagliavini, Fabrizio ^c   more..

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g UNIVERSITY OF PARMA   (Italy)

^h MARIA VITTORIA HOSPITAL   (Italy)

ⁱ UNIVERSITÉ DE STRASBOURG   (France)

^j UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^k UNIVERSITY HOSPITAL OF NANCY   (France)

^l INSERM   (France)

^m ISTITUTO SUPERIORE DI SANITÀ   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; PLACEBO;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRANCE; GENE; GENOTYPE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRNP GENE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SPORADIC CREUTZFELDT JAKOB DISEASE; SURVIVAL TIME; URTICARIA;

AGED; CREUTZFELDT-JAKOB SYNDROME; DOUBLE-BLIND METHOD; DOXYCYCLINE; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HUMANS; MALE; MEDICAL FUTILITY; MIDDLE AGED; TREATMENT FAILURE;

EID: 84892542910     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70307-7     Document Type: Article

References (36)

1. Budka H, Head MW, Ironside JW, Gambetti P, Parchi P, Tagliavini F Sporadic Creutzfeldt-Jakob disease. Neurodegeneration: the molecular pathology of dementia and movement disorders 2011, 322-335. Blackwell, Oxford. D.W. Dickson, R.O. Weller (Eds.).
2. Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, Gambetti P Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol 2012, 11:618-628.
3. Colby DW, Prusiner SB Prions. Cold Spring Harb Perspect Biol 2011, 3:a006833.
4. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999, 46:224-233.
5. Hill AF, Joiner S, Wadsworth JD, et al. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain 2003, 126:1333-1346.
6. Puoti G, Giaccone G, Mangieri M, et al. Sporadic Creutzfeldt-Jakob disease: the extent of microglia activation is dependent on the biochemical type of PrPSc. J Neuropathol Exp Neurol 2005, 64:902-909.
7. Pocchiari M, Puopolo M, Croes EA, et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain 2004, 127:2348-2359.
8. Trevitt CR, Collinge J A systematic review of prion therapeutics in experimental models. Brain 2006, 129:2241-2265.
9. Rossi G, Salmona M, Forloni G, Bugiani O, Tagliavini F Therapeutic approaches to prion diseases. Clin Lab Med 2003, 23:187-208.
10. Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 2004, 62:714-718.
11. Haïk S, Brandel JP, Salomon D, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology 2004, 63:2413-2415.
12. Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009, 8:334-344.
13. Geschwind MD, Kuo AL, Wong KS, et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology 2013, 81:2015-2023.
14. Bone I, Belton L, Walker AS, Darbyshire J Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol 2008, 15:458-464.
15. Tsuboi Y, Doh-Ura K, Yamada T Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology 2009, 29:632-636.
16. Merlini G, Ascari E, Amboldi N, et al. Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995, 92:2959-2963.
17. Tagliavini F, McArthur RA, Canciani B, et al. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science 1997, 276:1119-1122.
18. Tagliavini F, Forloni G, Colombo L, et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol 2000, 300:1309-1322.
19. Forloni G, Iussich S, Awan T, et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci USA 2002, 99:10849-10854.
20. De Luigi A, Colombo L, Diomede L, et al. The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS One 2008, 3:e1888.
21. Forloni G, Salmona M, Marcon G, Tagliavini F Tetracyclines and prion infectivity. Infect Disord Drug Targets 2009, 9:23-30.
22. Stoilova T, Colombo L, Forloni G, Tagliavini F, Salmona M A new face for old antibiotics: tetracyclines in treatment of amyloidoses. J Med Chem 2013, 56:5987-6006.
23. Tagliavini F Prion therapy: Tetracyclic compounds in animal models and patients with Creutzfeldt-Jakob disease. Alzheimers Dement 2008, 4(suppl):T149-T150.
24. Mac Dougall C, Chambers H Protein synthesis inhibitors and miscellaneous antibacterial agents. Goodman and Gilman's the pharmacological basis of therapeutics 2011, 1521-1547. McGraw-Hill, New York. 12th edn. L. Brunton (Ed.).
25. Ponto C, Zerr I Prionerkrankungen-welche Rolle spielen sie heute?. In|Fo|Neurologie & Psychiatrie 2013, 15:2-8.
26. Zeidler M, Gibbs CJ, Meslin F WHO manual for strengthening diagnosis and surveillance of Creutzfeldt-Jakob disease. WHO/EMC/ZDI/98.11 1998, World Health Organization, Geneva, (accessed June 17, 2012). http://www.who.int/iris/handle/10665/66394.
27. Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 2009, 132:2659-2668.
28. Pocock SJ Current issues in the design and interpretation of clinical trials. BMJ (Clin Res Ed) 1985, 290:39-42.
29. Giaccone G, Canciani B, Puoti G, et al. Carnoy's fixative improves the immunohistochemistry of the proteinase K-resistant prion protein. Brain Pathol 2000, 10:31-37.
30. Levavasseur E, Laffont-Proust I, Morain E, et al. Regulating factors of PrP glycosylation in Creutzfeldt-Jakob disease-implications for the dissemination and the diagnosis of human prion strains. PLoS One 2008, 3:e2786.
31. Whitehead J The design and analysis of sequential clinical trials 1992, Ellis Horwood Ltd, Chichester UK. 2nd edn.
32. Lang AE Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med 2010, 16:1223-1226.
33. McGuire LI, Peden AH, Orrú CD, et al. Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol 2012, 72:278-285.
34. Perry DC, Geschwind MD Prion disease: thorough work-up and new diagnostic criteria needed for CJD. Nat Rev Neurol 2011, 7:479-480.
35. Colovic M, Caccia S Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 791:337-343.
36. Hannaoui S, Gougerot A, Privat N, et al. Cycline efficacy on the propagation of human prions in primary cultured neurons is strain-specific. J Infect Dis 2013, published online Nov 21. 10.1093/infdis/jit623.